甲氨蝶呤单药及联合治疗类风湿关节炎的不良事件发生率与预测因素:系统综述
RCT中总AE汇总发生率为80.1%(95%CI: 73.5, 85.9),观察性研究中为23.1%(95%CI: 12.3, 36.0);严重AE分别为9.5%(95%CI: 7.4, 11.7)和2.1%(95%CI: 1.0, 3.4)。因AE停用MTX在观察性研究中为15.5%(95%CI: 9.6, 22.3),高于RCT的6.7%(95%CI: 4.7, 8.9);胃肠道事件最常见(汇总发生率32.7%,95%CI: 18.5, 48.7)。
要点
- RCT中MTX总AE汇总发生率为80.1%,观察性研究为23.1%。
- 严重AE汇总发生率RCT为9.5%,观察性研究为2.1%。
- 因AE停用MTX观察性研究为15.5%,高于RCT的6.7%。
核心结论
- 该系统综述提供了RA患者使用MTX相关AE发生率的最新汇总数据。
- 研究结果应告知患者,以帮助其在开始MTX治疗前做出知情选择。
研究设计与样本
- 检索三个数据库,纳入报告未使用过MTX的RA患者AE的RCT和观察性队列研究。
- 采用随机效应荟萃分析按研究设计分层汇总AE发生率。
主要发现
- RCT中总AE汇总发生率为80.1%(95%CI: 73.5, 85.9),观察性研究中为23.1%(95%CI: 12.3, 36.0)。
- RCT中严重AE汇总发生率为9.5%(95%CI: 7.4, 11.7),观察性研究中为2.1%(95%CI: 1.0, 3.4)。
- 因AE停用MTX在观察性研究中为15.5%(95%CI: 9.6, 22.3),高于RCT的6.7%(95%CI: 4.7, 8.9)。
- 胃肠道事件是最常报告的AE,汇总发生率为32.7%(95%CI: 18.5, 48.7)。
- 五项研究探讨了AE预测因素:RF状态、BMI和HAQ评分与因AE停用MTX相关;ACPA阴性、吸烟和肌酐升高与肝酶升高风险增加相关。
临床怎么用
- 临床医生可参考本综述的AE发生率数据,在起始MTX治疗前与患者沟通治疗风险。
- 对于RF阳性、BMI较高或HAQ评分较高的患者,应关注因AE停用MTX的风险。
- 对于ACPA阴性、吸烟或肌酐升高的患者,应监测肝酶升高风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This systematic review aims to summarize rates of adverse events (AEs) in patients with RA or inflammatory arthritis starting MTX as monotherapy or in combination with other csDMARDs, and to identify reported predictors of AEs. METHODS: Three databases were searched for studies reporting AEs in MTX-naïve patients with RA. Randomized controlled trials (RCTs) and observational cohort studies were included. Prevalence rates of AEs were pooled using random effects meta-analysis, stratified by study design. RESULTS: Forty-six articles (34 RCTs and 12 observational studies) were identified. The pooled prevalence of total AEs was 80.1% in RCTs (95% CI: 73.5, 85.9), compared with 23.1% in observational studies (95% CI: 12.3, 36.0). The pooled prevalence of serious AEs was 9.5% in RCTs (95% CI: 7.4, 11.7), and 2.1% in observational studies (95% CI: 1.0, 3.4). MTX discontinuation due to AEs was higher in observational studies (15.5%, 95% CI: 9.6, 22.3) compared with RCTs (6.7%, 95% CI: 4.7, 8.9). Gastrointestinal events were the most commonly reported AEs (pooled prevalence: 32.7%, 95% CI: 18.5, 48.7). Five studies examined predictors of AEs. RF status, BMI and HAQ score were associated with MTX discontinuation due to AEs; ACPA negativity, smoking and elevated creatinine were associated with increased risk of elevated liver enzymes. CONCLUSION: The review provides an up-to-date overview of the prevalence of AEs associated with MTX in patients with RA. The findings should be communicated to patients to help them make informed choices prior to commencing MTX.
引用
- Sherbini AA, Sharma SD, Gwinnutt JM, et al. Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2021. PMID: 33909898. doi:10.1093/rheumatology/keab304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。